Thermo Fisher Scientific Inc. $TMO Shares Acquired by Liberty Capital Management Inc.

Liberty Capital Management Inc. boosted its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 0.3% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 16,592 shares of the medical research company’s stock after purchasing an additional 46 shares during the period. Thermo Fisher Scientific comprises approximately 1.4% of Liberty Capital Management Inc.’s investment portfolio, making the stock its 22nd biggest holding. Liberty Capital Management Inc.’s holdings in Thermo Fisher Scientific were worth $6,727,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Brighton Jones LLC raised its position in shares of Thermo Fisher Scientific by 28.9% in the fourth quarter. Brighton Jones LLC now owns 4,409 shares of the medical research company’s stock worth $2,293,000 after acquiring an additional 988 shares during the period. Revolve Wealth Partners LLC grew its stake in Thermo Fisher Scientific by 4.2% during the 4th quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company’s stock valued at $255,000 after acquiring an additional 20 shares in the last quarter. NBC Securities Inc. grew its stake in Thermo Fisher Scientific by 125,200.0% during the 1st quarter. NBC Securities Inc. now owns 2,506 shares of the medical research company’s stock valued at $1,246,000 after acquiring an additional 2,504 shares in the last quarter. Harbor Investment Advisory LLC grew its stake in Thermo Fisher Scientific by 30.5% during the 1st quarter. Harbor Investment Advisory LLC now owns 389 shares of the medical research company’s stock valued at $194,000 after acquiring an additional 91 shares in the last quarter. Finally, Merit Financial Group LLC boosted its holdings in Thermo Fisher Scientific by 19.2% in the 1st quarter. Merit Financial Group LLC now owns 11,746 shares of the medical research company’s stock valued at $5,845,000 after purchasing an additional 1,895 shares during the last quarter. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Thermo Fisher Scientific Stock Performance

Shares of NYSE TMO opened at $484.70 on Wednesday. The company has a market cap of $183.03 billion, a PE ratio of 28.03, a price-to-earnings-growth ratio of 2.51 and a beta of 0.75. Thermo Fisher Scientific Inc. has a 12 month low of $385.46 and a 12 month high of $620.00. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.93 and a quick ratio of 1.50. The company has a 50-day simple moving average of $478.98 and a 200-day simple moving average of $446.98.

Thermo Fisher Scientific (NYSE:TMO) last released its earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.22 by $0.14. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The firm had revenue of $10.86 billion during the quarter, compared to the consensus estimate of $10.68 billion. During the same period in the previous year, the firm earned $5.37 earnings per share. Thermo Fisher Scientific’s revenue was up 2.9% compared to the same quarter last year. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. On average, equities analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, October 15th. Shareholders of record on Monday, September 15th will be given a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 0.4%. The ex-dividend date of this dividend is Monday, September 15th. Thermo Fisher Scientific’s payout ratio is 9.95%.

Insider Buying and Selling at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 400 shares of Thermo Fisher Scientific stock in a transaction that occurred on Friday, July 25th. The shares were sold at an average price of $479.98, for a total transaction of $191,992.00. Following the transaction, the executive vice president directly owned 22,367 shares of the company’s stock, valued at $10,735,712.66. The trade was a 1.76% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction that occurred on Friday, August 22nd. The shares were sold at an average price of $500.96, for a total transaction of $5,009,600.00. Following the transaction, the chief executive officer directly owned 115,174 shares in the company, valued at approximately $57,697,567.04. This trade represents a 7.99% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 30,066 shares of company stock valued at $14,182,963 over the last ninety days. Corporate insiders own 0.33% of the company’s stock.

Analyst Ratings Changes

Several brokerages have recently commented on TMO. Evercore ISI decreased their price objective on shares of Thermo Fisher Scientific from $500.00 to $480.00 and set an “outperform” rating on the stock in a report on Tuesday, July 8th. Hsbc Global Res lowered shares of Thermo Fisher Scientific from a “strong-buy” rating to a “hold” rating in a report on Thursday, July 24th. William Blair began coverage on shares of Thermo Fisher Scientific in a research report on Monday, August 18th. They issued an “outperform” rating on the stock. Wall Street Zen downgraded shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a research report on Sunday, September 7th. Finally, Robert W. Baird increased their price target on shares of Thermo Fisher Scientific from $553.00 to $567.00 and gave the stock an “outperform” rating in a research note on Thursday, July 24th. Fifteen investment analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the stock. According to MarketBeat.com, Thermo Fisher Scientific currently has a consensus rating of “Moderate Buy” and an average target price of $583.53.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.